

Dear healthcare provider,

I am interested in a prescription for TRUVADA® as part of PrEP (Pre-Exposure Prophylaxis). TRUVADA® is a combination of two HIV medicines (emtricitabine/tenofovir disoproxil fumarate), and has been approved by the FDA since July 2012, for daily use as part of a comprehensive prevention strategy (PrEP) to reduce the chance of a HIV-negative person from acquiring HIV.

I understand that this is a daily medication, and with your help and guidance, I would like to move forward with a prescription, pending my candidacy. Here is some information I have gathered to understand next steps:

- Detailed past and present sexual practices to determine risk.
- Confirmatory negative acute HIV-1 status (Last exposure should be >1 month ago)
- Creatinine Urine Test (Urine 24-Hour Volume Test) for possible renal dysfunction.
Do not prescribe TRUVADA® for uninfected individuals with an estimated CrCL below 60 mL/min
- Test for HBV (Hepatitis B Virus). Offer hepatitis vaccinations if appropriate.
Patients infected with HBV can experience severe acute exacerbations, and would need to be monitored.
- Discuss any potential drug interactions before prescribing TRUVADA®
- Counsel & confirm an understanding of daily adherence to maintain the effectiveness of TRUVADA®.
- Routine STI and HIV screening every 3 months.

For additional specific information regarding TRUVADA® as PrEP refer to
www.truvadapreprems.com

I understand that using TRUVADA® as prescribed for PrEP does not excuse me from using condoms or other safer sex practices, as it does not offer any protection from other STIs, but with my daily adherence, I can greatly reduce the chance of acquiring HIV.

*The use of trade names and commercial sources is for identification only and does not imply endorsement by Impulse Orlando.

This letter has been made freely available by Impulse Orlando, a non-profit HIV Awareness Organization.

For more information please visit impulseorlando.org

Last Modified: January 24, 2016